Brazil’s health regulator, Anvisa announced restriction on the import of the Sputnik V from Russia. Anvisa’s decision of disapproving the Russian made vaccine comes after it’s technical staff labelled it to be equipped with serious risks and defects. So far only Brazil has refused the usage of Sputnik V.
However, The Russian Direct Investment Fund (RDIF) has declined the comments by the health regulator. It states that the Sputnik V is safe and effective vaccine. Till now 61 countries have approved the usage of Sputnik.
A statement by RDIF says, “Anvisa’s decision to delay the registration of Sputnik V may have been politically motivated,” Further, “RDIF regrets the numerous attempts by some countries to oppose the Russian vaccine… including through pressure on foreign regulators.
Gustavo Mendes, manager of Anvisa’s medical and Biological products calls for rejection after adenovirus, a virus that could produce serious defects was discovered in Sputnik V.
Sputnik V efficacy
Meanwhile, as per Russian scientists Sputnik V is verified to be 97.6% effective against the novel coronavirus. The assessment is based on the data of people jabbed that stands to be 3.8 million.
Presently, The European Medicines Agency (EMA) is evaluating Sputnik V manufacturing procedure and might announce it’s usage in May or June.
As per the health ministry data about 27.3 million people have received the first dose of the vaccine. COVID cases in the country have mounted to 14.4 million in the past 24 hours. Fatalities – 40,000 in the country and no. of patients recovered are 12.7 million.
The United States and Brazil are seeing the worst of the pandemic. Brazil secures the third rank in countries with the most number of cases. Also, The USA and India have managed to secure the first and second positions, respectively.
The virus has infected over 148 million people worldwide, and the number of deaths had reached 3.13 million.
ALSO READ: COVID-19 Hug Image From Brazil Named World Press Photo Of The Year